相关实验视频
Updated: Jul 11, 2025

07:42
A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
179
用β阻塞剂和败血症患者之间的关联:一项队列研究
Qilin Yang1, Tianyu Kong1, Ziping Bao1
1Department of Critical Care, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Frontiers in medicine
|November 15, 2023
概括
在败血症患者中使用β-阻断剂与减少住院死亡率有关. 在各种子组中观察到这种关联,这表明在败血症管理中存在潜在的益处.
科学领域:
- 临界护理医学 临界护理医学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 败血症是一种危及生命的疾病,死亡率高.
- 贝塔抑制剂在败血症管理中的作用仍然不完全理解.
- 确定改善败血症结果的因素对于临床实践至关重要.
研究的目的:
- 对被诊断患有败血症的患者使用β-阻断剂和住院死亡率之间的关联进行调查.
- 通过使用大型,现实世界的患者数据集来分析这种关联.
主要方法:
- 使用MIMIC-IV和eICU数据库进行回顾性队列研究.
- 包括61,751名患有败血症的患者.
- 倾向性得分匹配和反向概率加权被用来控制混因素.
主要成果:
- 总体而言,住院死亡率为15.3% (MIMIC-IV) 和13.6% (eICU).
- 在这两组数据中,β-阻断剂的使用与较低的住院死亡率显著相关 (HR < 1, p < 0.001).
- 这种关联在各种子组中保持一致,包括性别,年龄,心率,APSIII和败血性休克.
结论:
- 贝塔阻断剂的使用似乎与败血症患者的住院死亡率降低有关.
- 这些发现表明β-阻断剂在败血症中具有潜在的保护作用.
- 需要进一步的随机对照试验来证实这些观察结果.
相关概念视频
Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
864
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
864
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
632
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
632
Antihypertensive Drugs: Types of β-Blockers
701
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
701
Antihypertensive Drugs: Action of β1 Blockers
455
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
455
Adrenergic Antagonists: ɑ and β-Receptor Blockers
493
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
493

